Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections

ABSTRACT

Avibactam, a novel β-lactamase inhibitor, has recently been co-formulated with ceftazidime and approved for use in patients with complicated intra-abdominal and urinary tract infections, where no better treatment alternative exists. The basis for its FDA approval has been the extensive clinical experience with ceftazidime and the demonstration in vitro and in animal models that the addition of avibactam reverses resistance to ceftazidime in extended-spectrum β-lactamase and some carbapenemase-producing Enterobacteriaceae. Early clinical data are promising, with efficacy demonstrated in patients with complicated intra-abdominal and urinary tract infections. This review will summarize the in vitro, animal and clinical data available on this agent to date.

KEYWORDS:

• Ceftazidime-avibactam
• Gram-negative infection
• antibiotic resistance
• β-lactamase
• β-lactamase inhibitor
• carbapenem-resistant Enterobacteriaceae

Financial & competing interests disclosure

Y Golan is a consultant for Merck, Pfizer and Allergan; a speaker for Merck, Pfizer, Allergan, Theravance and The Medicines Company; and has received research grants from Merck and Allergan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.